Self-driving cars. Genetic editing. Intelligent robots.

When we decode biology, we have the opportunity to radically improve people’s lives.

Advanced technologies are part of the dramatic shift happening all around us: the fourth industrial revolution. A range of advanced technologies fusing the physical and digital worlds are impacting everything we do, and drug discovery is no different. With tools like machine learning, CRISPR, high-throughput screening and automation, we can reengineer drug discovery to be more predictive, precise and productive.

At Recursion, our ambition is to industrialize drug discovery. It is bold, but it is not for the sake of being bold. It is because we care about patients and their loved ones, our people and the communities in which we live.

By finding better treatments using a novel approach:

Today, 90% of drugs that enter clinical trials never make it to market. This failure rate hurts patients that are waiting for therapy and incurs huge costs that drive up drug prices. We are taking a novel, data-first approach to finding new medicines. Our growing map of human cellular biology allows us to probe the complexity of disease and discover potential medicines by approaching drug discovery in a new way. This is the challenge we care so deeply about solving: finding better medicines and making them more accessible to the people who need them.

By driving down costs:

R&D costs are a major driver of high drug prices. It takes more than one billion dollars to get a drug from discovery to market. Why? It takes more than a decade using traditional R&D approaches and 9 in 10 drugs in development fail to make it. With long timelines and high failure rates it’s no wonder those drugs become expensive for patients, payers and the system. We can do better. By making R&D less of an art and more of a data-driven process, we can drive down uncertainty and in doing so, optimize the cost and speed of discovery.

By helping patients and those who love them:

Why do we care about finding better, accessible medicines? Because patients need new therapies, yesterday. As a company that got its start in rare diseases, we have seen firsthand how many patients — and their loved ones — find themselves in a dark situation, faced with a new diagnosis, and without an acceptable treatment path forward. We hope to give these patients light. By doing so we help their families, friends, colleagues and communities see the light, too.

By sharing what we learn:

Human biology is incredibly complex. It requires developing smarter solutions that leverage the latest technologies and a more open, collaborative approach. In 2019, we released the first open-source biological images dataset for the broader machine learning community to help us develop new algorithms that aid drug discovery in RxRx. We will continue to share what we learn, knowing that Recursion’s contribution to our greater understanding of human biology is just as important as the medicines we advance.